Metformin-associated lactic acidosis and acute kidney injury in the era of COVID-19.

COVID-19, provoked by SARS-CoV-2, constitutes a global health issue with high rates of mortality. The presence of diabetes mellitus is associated with severe coronavirus COVID-19 as it is related to increased death rates in patients admitted to the intensive care unit. Acute kidney injury is a frequent complication among patients hospitalized for COVID-19 and is met with high morbidity and mortality. Here, we present a case of a diabetic patient with acute kidney injury, metformin-associated lactic acidosis, and COVID-19. Lactic acidosis is a relatively rare but noteworthy complication of metformin use. However, the combination of those life-threatening situations could prove fatal for the patients despite optimal medical care.

[1]  C. Tsioufis,et al.  Inflammatory Mediators of Platelet Activation: Focus on Atherosclerosis and COVID-19 , 2021, International journal of molecular sciences.

[2]  G. Paolisso,et al.  Does poor glycaemic control affect the immunogenicity of the COVID‐19 vaccination in patients with type 2 diabetes: The CAVEAT study , 2021, Diabetes, obesity & metabolism.

[3]  Ramona Suharoschi,et al.  Endothelial Dysfunction, Inflammation, and Oxidative Stress in COVID-19—Mechanisms and Therapeutic Targets , 2021, Oxidative medicine and cellular longevity.

[4]  C. Tsioufis,et al.  Inflammatory Mechanisms Contributing to Endothelial Dysfunction , 2021, Biomedicines.

[5]  F. Crea,et al.  Inflammatory Mechanisms in COVID-19 and Atherosclerosis: Current Pharmaceutical Perspectives , 2021, International journal of molecular sciences.

[6]  Chih-Wei Yang,et al.  Endothelial Dysfunction for Acute Kidney Injury in Coronavirus Disease 2019: How Concerned Should We Be? , 2021, Nephron.

[7]  R. Franco,et al.  Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte , 2021, Cardiovascular Diabetology.

[8]  A. Malhotra,et al.  Inpatient Use of Metformin and Acarbose Is Associated with Reduced Mortality of COVID-19 Patients with Type 2 Diabetes Mellitus , 2021, Research Square.

[9]  P. Duan,et al.  Effects of metformin, insulin on COVID-19 patients with pre-existed type 2 diabetes: A multicentral retrospective study , 2021, Life Sciences.

[10]  G. Lazarus,et al.  Is there a need to reconsider the use of metformin in COVID-19 patients with type 2 diabetes mellitus? , 2021, International Journal of Diabetes in Developing Countries.

[11]  L. Tamariz,et al.  Metformin is associated with lower hospitalizations, mortality and severe coronavirus infection among elderly medicare minority patients in 8 states in USA , 2021, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[12]  V. Rigalleau,et al.  Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study , 2021, Diabetologia.

[13]  9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. , 2020, Diabetes care.

[14]  J. Bae,et al.  COVID-19 and diabetes mellitus: from pathophysiology to clinical management , 2020, Nature Reviews Endocrinology.

[15]  L. Forni,et al.  COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup , 2020, Nature Reviews Nephrology.

[16]  P. Ye,et al.  Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes , 2020, Cell Metabolism.

[17]  C. Vlachopoulos,et al.  Hospital attendance and admission trends for cardiac diseases during the COVID-19 outbreak and lockdown in Greece , 2020, Public Health.

[18]  A. Scheen.  Metformin and COVID-19: From cellular mechanisms to reduced mortality , 2020, Diabetes & Metabolism.

[19]  F. Ovalle,et al.  METFORMIN USE IS ASSOCIATED WITH REDUCED MORTALITY IN A DIVERSE POPULATION WITH COVID-19 AND DIABETES , 2020, medRxiv.

[20]  D. Tousoulis,et al.  The impact of COVID-19 pandemic on adult cardiac surgery procedures , 2020, Hellenic Journal of Cardiology.

[21]  G. Paolisso,et al.  Hyperglycaemia on admission to hospital and COVID-19 , 2020, Diabetologia.

[22]  S. Sendil,et al.  Metformin Associated Lactic Acidosis in the Intensive Care Unit: A Rare Condition Mimicking Sepsis , 2020, Cureus.

[23]  J. Radhakrishnan,et al.  Outcomes for Patients With COVID-19 and Acute Kidney Injury: A Systematic Review and Meta-Analysis , 2020, Kidney international reports.

[24]  D. Vojta,et al.  Observational Study of Metformin and Risk of Mortality in Patients Hospitalized with Covid-19 , 2020, medRxiv.

[25]  G. Paolisso,et al.  Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19 , 2020, Cardiovascular Diabetology.

[26]  S. Hadjadj,et al.  Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study , 2020, Diabetologia.

[27]  Dong Liu,et al.  Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis , 2020, The American journal of tropical medicine and hygiene.

[28]  G. Paolisso,et al.  Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients , 2020, Diabetes & Metabolism.

[29]  G. Paolisso,et al.  Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control? , 2020, Diabetes Care.

[30]  Anlin Peng,et al.  Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication , 2020, Diabetes Care.

[31]  Kenar D. Jhaveri,et al.  Acute kidney injury in patients hospitalized with COVID-19 , 2020, Kidney International.

[32]  Dominique Maiter,et al.  COVID-19 in diabetic patients: Related risks and specifics of management , 2020, Annales d'Endocrinologie.

[33]  R. Marfella,et al.  Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence , 2020, Journal of clinical medicine.

[34]  Cassandra Kien,et al.  A Unique Case of Metformin-associated Severe Lactic Acidosis Without Preexisting Renal Disease: Perspectives on Prolonged Dialysis and Education for Prevention , 2020, Cureus.

[35]  K. Taxis,et al.  Extracorporeal treatment of metforminassociated lactic acidosis in clinical practice: a retrospective cohort study , 2020, European Journal of Clinical Pharmacology.

[36]  Xiaolong Qi,et al.  Real estimates of mortality following COVID-19 infection , 2020, The Lancet Infectious Diseases.

[37]  R. Sinert,et al.  Do Patients Die with or from Metformin-Associated Lactic Acidosis (MALA)? Systematic Review and Meta-analysis of pH and Lactate as Predictors of Mortality in MALA , 2020, Journal of Medical Toxicology.

[38]  R. Marfella,et al.  Metformin Lactic Acidosis: should we still be afraid? , 2019, Diabetes research and clinical practice.

[39]  R. Walker,et al.  The Association between Metformin Therapy and Lactic Acidosis , 2019, Drug Safety.

[40]  G. Regolisti,et al.  Treatment of Metformin Intoxication Complicated by Lactic Acidosis and Acute Kidney Injury: The Role of Prolonged Intermittent Hemodialysis. , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[41]  S. Gosselin,et al.  Toxicokinetics of Metformin During Hemodialysis , 2017, Kidney international reports.

[42]  D. Santoro,et al.  Metformin-related lactic acidosis: is it a myth or an underestimated reality? , 2016, Renal failure.

[43]  R. Hoffman,et al.  Extracorporeal Treatment for Metformin Poisoning: Systematic Review and Recommendations From the Extracorporeal Treatments in Poisoning Workgroup , 2015, Critical care medicine.

[44]  S. Suh.  Metformin-Associated Lactic Acidosis , 2015, Endocrinology and metabolism.

[45]  H Connor,et al.  Metformin kinetics in healthy subjects and in patients with diabetes mellitus. , 1981, British journal of clinical pharmacology.

[46]  ScienceDirect,et al.  Annales françaises d'anesthésie et de réanimation , 1982 .